<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01378858</url>
  </required_header>
  <id_info>
    <org_study_id>2010-279</org_study_id>
    <secondary_id>K23DA025736</secondary_id>
    <nct_id>NCT01378858</nct_id>
  </id_info>
  <brief_title>Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients</brief_title>
  <official_title>Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial will evaluate whether varenicline directly observed therapy provided at&#xD;
      a methadone clinic is more efficacious than self-administered varenicline for promoting&#xD;
      smoking cessation and enhancing adherence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a marked prevalence of tobacco use and tobacco-related disease among methadone&#xD;
      maintenance patients. Varenicline's demonstrated efficacy may not be generalizable to&#xD;
      methadone maintained smokers because of poor adherence, which is highly prevalent among drug&#xD;
      users. Adherence to smoking cessation medication is strongly associated with cessation, and&#xD;
      is one of the few factors shown to increase cessation among methadone maintained smokers, but&#xD;
      strategies to promote smoking cessation medication adherence have not been evaluated in&#xD;
      methadone patients. Based on the Information, Motivation, and Behavior model, the&#xD;
      investigators plan a directly observed therapy (DOT)-based intervention targeting behavioral&#xD;
      skills necessary for optimal adherence. Because methadone clinic-based DOT interventions have&#xD;
      been shown to improve medication adherence and clinical outcomes in HIV and TB, the&#xD;
      investigators plan to determine in a randomized trial whether DOT varenicline provided at a&#xD;
      methadone clinic is more efficacious than self-administered varenicline for promoting smoking&#xD;
      cessation and enhancing adherence. The investigators will also evaluate moderating effects of&#xD;
      drug and alcohol use and psychiatric symptoms on DOT effects. The investigators hypothesize&#xD;
      subjects in the mDOT arm will have greater 7 day point prevalence abstinence at 12 weeks,&#xD;
      reduction in cigarettes/day, time to first daily cigarette, ≥ 24 hour quit attempts, and 7&#xD;
      day point prevalence abstinence at 24 weeks compared to subjects receiving self administered&#xD;
      varenicline. The investigators also hypothesize that adherence in the mDOT arm will be higher&#xD;
      than in the TAU arm. Lastly the investigators hypothesize that ongoing illicit drug use and&#xD;
      psychiatric symptoms will moderate the effect of mDOT on adherence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Varenicline Adherence as Measured by Pill Count</measure>
    <time_frame>Weeks 0-1, 1-2, 2-3, 4-6, 7-9, 10-12</time_frame>
    <description>Pill count adherence, measured as pills taken divided by pills dispensed, analyzed as a continuous measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tobacco Abstinence Biochemically Verified With Expired Carbon Monoxide (CO) &lt; 8 p.p.m. at 12 Weeks</measure>
    <time_frame>Week 12 of treatment</time_frame>
    <description>Number of participants achieving self reported, seven day point prevalence abstinence, biochemically verified with expired carbon monoxide (CO) &lt; 8 p.p.m., missing = smoking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tobacco Abstinence Biochemically Verified With Expired Carbon Monoxide (CO) &lt; 8 p.p.m. at 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Number of participants achieving self reported, seven day point prevalence abstinence, biochemically verified with expired carbon monoxide (CO) &lt; 8 p.p.m.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <condition>Medication Adherence</condition>
  <arm_group>
    <arm_group_label>Varenicline treatment as usual (TAU)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the TAU arm will self administer varenicline for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline directly observed therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.</description>
    <arm_group_label>Varenicline directly observed therapy</arm_group_label>
    <arm_group_label>Varenicline treatment as usual (TAU)</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Smoked at least 100 cigarettes/lifetime&#xD;
&#xD;
          -  Smoke 5 or more cigarettes per day&#xD;
&#xD;
          -  Interested in quitting smoking (preparation or contemplation stage of change)&#xD;
&#xD;
          -  Enrolled in Einstein/Montefiore methadone program for 12 weeks or more&#xD;
&#xD;
          -  Receiving methadone in clinic three, four, five or six times per week&#xD;
&#xD;
          -  No more than 2 methadone clinic misses in prior 14 days&#xD;
&#xD;
          -  Agree to use contraception for the duration of the trial (among women with&#xD;
             reproductive potential)&#xD;
&#xD;
          -  Willing to participate in all study components&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious or unstable HIV/AIDS, liver, cardiovascular, or pulmonary disease&#xD;
&#xD;
          -  Psychiatric instability&#xD;
&#xD;
          -  Women who are pregnant, breastfeeding, or contemplating pregnancy&#xD;
&#xD;
          -  Creatinine clearance &lt;30 mL/min&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shadi Nahvi, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <results_first_submitted>October 19, 2020</results_first_submitted>
  <results_first_submitted_qc>March 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2021</results_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Shadi Nahvi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Substance-Related Disorders</keyword>
  <keyword>medication adherence</keyword>
  <keyword>Methadone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Varenicline Treatment as Usual (TAU)</title>
          <description>Subjects in the TAU arm will self administer varenicline for 12 weeks.&#xD;
Varenicline: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Varenicline Directly Observed Therapy</title>
          <description>Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.&#xD;
Varenicline: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Varenicline Treatment as Usual (TAU)</title>
          <description>Subjects in the TAU arm will self administer varenicline for 12 weeks.&#xD;
Varenicline: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Varenicline Directly Observed Therapy</title>
          <description>Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.&#xD;
Varenicline: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="45" upper_limit="52"/>
                    <measurement group_id="B2" value="49" lower_limit="46" upper_limit="53"/>
                    <measurement group_id="B3" value="49" lower_limit="45" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mutliracial/multiethnic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes smoked per day</title>
          <units>cigarettes smoked per day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="8" upper_limit="15"/>
                    <measurement group_id="B2" value="12" lower_limit="8" upper_limit="20"/>
                    <measurement group_id="B3" value="10" lower_limit="8" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expired carbon monoxide</title>
          <description>A measure of the amount of carbon monoxide on a person's breath, which is checked using a Smokerlyzer monitor (Bedfont Scientific).</description>
          <units>parts per million</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="B2" value="8" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="B3" value="7" lower_limit="5" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fagerstrom Test of Nicotine Dependence score</title>
          <description>In scoring the Fagerstrom Test for Nicotine Dependence, yes/no items are scored from 0 to 1 and multiple-choice items are scored from 0 to 3. The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="B2" value="5" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="B3" value="5" lower_limit="4" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ladder of change score</title>
          <description>The Ladder is a continuous measure of motivation to change smoking where a score of 1 indicates low readiness to quit smoking and a score of 10 indicates high readiness to quit smoking.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="7" upper_limit="8"/>
                    <measurement group_id="B2" value="8" lower_limit="6" upper_limit="8"/>
                    <measurement group_id="B3" value="8" lower_limit="6" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quit importance</title>
          <description>Quit importance measures importance of quitting smoking for participants on a scale from 1 to 10 where 1 is not important and 10 is highly important</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="9" upper_limit="10"/>
                    <measurement group_id="B2" value="10" lower_limit="9" upper_limit="10"/>
                    <measurement group_id="B3" value="10" lower_limit="9" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quit confidence</title>
          <description>Quit confidence measures confidence in quitting smoking for participants on a scale from 1 to 10 where 1 is not confident at all and 10 is highly confident</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="B2" value="8" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="B3" value="8" lower_limit="5" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any past quit attempts</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preferred brand of cigarettes menthol</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with unstable housing</title>
          <description>Living in a shelter, temporary housing, hotel/motel, or on the street</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants currently employed</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants married or living with a partner</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime major depressive episode</title>
          <description>Assessed using the Mini-International Neuropsychiatric Interview 6.0.0. The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a short structured diagnostic interview for assessing DSM-IV and ICD-10 psychiatric disorders.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime psychotic disorder</title>
          <description>Assessed using the Mini-International Neuropsychiatric Interview 6.0.0. The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a short structured diagnostic interview for assessing DSM-IV and ICD-10 psychiatric disorders.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifetime suicide attempt</title>
          <description>Assessed using the Columbia Suicide Severity Scale, a structured interview which assesses suicidal ideation, plans, intent, and behavior</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Severe global psychiatric symptoms</title>
          <description>Assessed using the Brief Symptom Inventory Global Severity Index, a 53-item self report scale, with scores dichotomized at a T score ≥ 63</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Currently receiving psychiatric treatment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with COPD/Asthma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with HIV/AIDS</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median duration methadone maintenance</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="3.3" upper_limit="8.9"/>
                    <measurement group_id="B2" value="5.6" lower_limit="3.3" upper_limit="8.9"/>
                    <measurement group_id="B3" value="5.6" lower_limit="3.3" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median methadone dose</title>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92" lower_limit="60" upper_limit="120"/>
                    <measurement group_id="B2" value="83.5" lower_limit="70" upper_limit="110"/>
                    <measurement group_id="B3" value="90" lower_limit="61.5" upper_limit="112.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Varenicline Adherence as Measured by Pill Count</title>
        <description>Pill count adherence, measured as pills taken divided by pills dispensed, analyzed as a continuous measure</description>
        <time_frame>Weeks 0-1, 1-2, 2-3, 4-6, 7-9, 10-12</time_frame>
        <population>Comparison of varenicline TAU and DOT groups</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline Treatment as Usual (TAU)</title>
            <description>Subjects in the TAU arm will self administer varenicline for 12 weeks.&#xD;
Varenicline: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Directly Observed Therapy</title>
            <description>Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.&#xD;
Varenicline: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Varenicline Adherence as Measured by Pill Count</title>
          <description>Pill count adherence, measured as pills taken divided by pills dispensed, analyzed as a continuous measure</description>
          <population>Comparison of varenicline TAU and DOT groups</population>
          <units>percentage pills taken/pills dispensed</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8" lower_limit="55.0" upper_limit="68.6"/>
                    <measurement group_id="O2" value="78.5" lower_limit="71.8" upper_limit="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tobacco Abstinence Biochemically Verified With Expired Carbon Monoxide (CO) &lt; 8 p.p.m. at 12 Weeks</title>
        <description>Number of participants achieving self reported, seven day point prevalence abstinence, biochemically verified with expired carbon monoxide (CO) &lt; 8 p.p.m., missing = smoking</description>
        <time_frame>Week 12 of treatment</time_frame>
        <population>intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline Treatment as Usual (TAU)</title>
            <description>Subjects in the TAU arm will self administer varenicline for 12 weeks.&#xD;
Varenicline: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Directly Observed Therapy</title>
            <description>Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.&#xD;
Varenicline: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tobacco Abstinence Biochemically Verified With Expired Carbon Monoxide (CO) &lt; 8 p.p.m. at 12 Weeks</title>
          <description>Number of participants achieving self reported, seven day point prevalence abstinence, biochemically verified with expired carbon monoxide (CO) &lt; 8 p.p.m., missing = smoking</description>
          <population>intent to treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tobacco Abstinence Biochemically Verified With Expired Carbon Monoxide (CO) &lt; 8 p.p.m. at 24 Weeks</title>
        <description>Number of participants achieving self reported, seven day point prevalence abstinence, biochemically verified with expired carbon monoxide (CO) &lt; 8 p.p.m.</description>
        <time_frame>24 weeks</time_frame>
        <population>Missing = smoking</population>
        <group_list>
          <group group_id="O1">
            <title>Varenicline Treatment as Usual (TAU)</title>
            <description>Subjects in the TAU arm will self administer varenicline for 12 weeks.&#xD;
Varenicline: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline Directly Observed Therapy</title>
            <description>Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.&#xD;
Varenicline: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tobacco Abstinence Biochemically Verified With Expired Carbon Monoxide (CO) &lt; 8 p.p.m. at 24 Weeks</title>
          <description>Number of participants achieving self reported, seven day point prevalence abstinence, biochemically verified with expired carbon monoxide (CO) &lt; 8 p.p.m.</description>
          <population>Missing = smoking</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 week intervention period, and 12 week post intervention follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Varenicline Treatment as Usual (TAU)</title>
          <description>Subjects in the TAU arm will self administer varenicline for 12 weeks.&#xD;
Varenicline: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Varenicline Directly Observed Therapy</title>
          <description>Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.&#xD;
Varenicline: Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Incident major depressive episode</sub_title>
                <description>Assessed using the Mini-International Neuropsychiatric Interview 6.0.0</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Incident psychotic disorder</sub_title>
                <description>Assessed using the Mini-International Neuropsychiatric Interview 6.0.0</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <description>Wishes to be dead, or thoughts of killing self, assessed using the Columbia Suicide Severity Scale</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Change in taste</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Change in appetite</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gas</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Change in concentration</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vivid/more frequent dreams</sub_title>
                <description>Assessed through structured questionnaire, assessing specific symptoms reported in varenicline clinical trials, and open-ended assessment</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shadi Nahvi, MD, MS</name_or_title>
      <organization>Albert Einstein College of Medicine</organization>
      <phone>718 920 5379</phone>
      <email>snahvi@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

